RMC-5552 | CAS#2382768-62-7 | Bi-Steric | Inhibitor | mTORC1

MedKoo Cat#: 122434 | Name: RMC-5552

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

RMC-5552 is a Selective Bi-Steric Inhibitor of mTORC1 for the Treatment of mTORC1-Activated Tumors. RMC-5552 showed very potent p4EBP1 inhibition (IC50 = 0.48 nM) with much lower pAKT inhibition (IC50 = 19 nM), resulting in mTORC1/mTORC2 selectivity approaching 40-fold.

Chemical Structure

RMC-5552

CAS#2382768-62-7

Theoretical Analysis

MedKoo Cat#: 122434

Name: RMC-5552

CAS#: 2382768-62-7

Chemical Formula: C93H136N10O24

Exact Mass: 1776.9729

Molecular Weight: 1778.16

Elemental Analysis: C, 62.82; H, 7.71; N, 7.88; O, 21.59

Price and Availability

Size	Price	Availability	Quantity
1mg	USD 950.00	2 Weeks
5mg	USD 2,650.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

RMC-5552, RMC5552, RMC 5552

IUPAC/Chemical Name

[(1R,2R,4S)-2-methoxy-4-[(2R)-2-[(1R,9S,12S,14R,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,14,18-trihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-2,3,10,20-tetraoxo-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraen-12-yl]propyl]cyclohexyl] N-[2-[2-[2-[2-[2-[2-[2-[2-[3-[6-[[4-amino-3-(2-amino-1,3-benzoxazol-5-yl)pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-3,4-dihydro-1H-isoquinolin-2-yl]-3-oxopropoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl]carbamate

InChi Key

IUTYTXDIGUNPAA-GKVGALOGSA-N

InChi Code

InChI=1S/C93H136N10O24/c1-59-16-12-11-13-17-60(2)77(113-8)54-71-24-19-65(7)93(112,127-71)86(108)89(109)102-30-15-14-18-73(102)90(110)124-78(55-74(104)61(3)49-64(6)84(107)85(115-10)83(106)63(5)48-59)62(4)50-66-21-25-76(79(52-66)114-9)126-92(111)96-29-33-117-35-37-119-39-41-121-43-45-123-47-46-122-44-42-120-40-38-118-36-34-116-32-28-80(105)101-31-27-68-51-67(20-22-70(68)57-101)56-103-88-81(87(94)97-58-98-88)82(100-103)69-23-26-75-72(53-69)99-91(95)125-75/h11-13,16-17,20,22-23,26,49,51,53,58-59,61-63,65-66,71,73-74,76-79,84-85,104,107,112H,14-15,18-19,21,24-25,27-48,50,52,54-57H2,1-10H3,(H2,95,99)(H,96,111)(H2,94,97,98)/b13-11+,16-12+,60-17+,64-49+/t59-,61-,62-,63-,65-,66+,71+,73+,74-,76-,77+,78+,79-,84-,85+,93-/m1/s1

SMILES Code

O=C(O[C@H]1[C@H](OC)C[C@H](C[C@H]([C@H](C[C@@H](O)[C@H](C)/C=C(C)/[C@@H](O)[C@H]2OC)OC([C@]3([H])CCCCN3C(C([C@@](O4)(O)[C@H](C)CC[C@@]4([H])C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C2=O)=O)=O)=O)C)CC1)NCCOCCOCCOCCOCCOCCOCCOCCOCCC(N5CC6=C(C=C(CN7N=C(C8=CC=C(OC(N)=N9)C9=C8)C%10=C(N)N=CN=C%107)C=C6)CC5)=O

Appearance

To be determined

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 1,778.16 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Burnett GL, Yang YC, Aggen JB, Pitzen J, Gliedt MK, Semko CM, Marquez A, Evans JW, Wang G, Won WS, Tomlinson ACA, Kiss G, Tzitzilonis C, Thottumkara AP, Cregg J, Mellem KT, Choi JS, Lee JC, Zhao Y, Lee BJ, Meyerowitz JG, Knox JE, Jiang J, Wang Z, Wildes D, Wang Z, Singh M, Smith JAM, Gill AL. Discovery of RMC-5552, a Selective Bi-Steric Inhibitor of mTORC1, for the Treatment of mTORC1-Activated Tumors. J Med Chem. 2022 Dec 19. doi: 10.1021/acs.jmedchem.2c01658. Epub ahead of print. PMID: 36533617. Liu Y, Zhang M, Jang H, Nussinov R. The allosteric mechanism of mTOR activation can inform bitopic inhibitor optimization. Chem Sci. 2023 Dec 7;15(3):1003-1017. doi: 10.1039/d3sc04690g. PMID: 38239681; PMCID: PMC10793652. Bhattacharyya S, Oblinger JL, Beauchamp RL, Kosa L, Robert F, Plotkin SR, Chang LS, Ramesh V. Preclinical evaluation of the third-generation, bi-steric mechanistic target of rapamycin complex 1-selective inhibitor RMC-6272 in NF2-deficient models. Neurooncol Adv. 2024 Feb 16;6(1):vdae024. doi: 10.1093/noajnl/vdae024. PMID: 38476930; PMCID: PMC10929445.